Health
Orsini Selected as the Exclusive Specialty Pharmacy and Home Infusion Partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm)
Orsini, a leader in rare disease pharmacy solutions, announced today that it is the exclusive specialty pharmacy partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm), an FDA-approved enzyme replacement therapy for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.. Read the full Prescribing Informati
About this update from Denali Therapeutics Inc.
[{"type":"text","content":"AVLAYAH is an FDA-approved intravenous enzyme replacement therapy for the pediatric treatment of Hunter syndrome.","length":113,"tagName":"p"},{"type":"text","content":"ELK GROVE VILLAGE, Ill., April 20, 2026 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, announced today that it is the exclusive specialty pharmacy partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm), an FDA-approved enzyme replacement therapy for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.. Read the full Prescribing Information here. As part of this program, Orsini will provide comprehensive home infusion support to ensure patients can access therapy in the comfort and convenience of their own homes, as recommended and supervised by a healthcare provider.","length":794,"tagName":"p"},{"type":"image","alt":"Orsini - Rare Disease Pharmacy Solutions (PRNewsfoto/Orsini Healthcare)","displaySize":"","headline":null,"caption":"Orsini - Rare Disease Pharmacy Solutions (PRNewsfoto/Orsini Healthcare)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":142,"url":"https://media.zenfs.com/en/prnewswire.com/dc40ba97383423273b15d3649bddbd5c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2h9mC.nsTQKlE2_Ub_6DIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI1MA--/https://media.zenfs.com/en/prnewswire.com/dc40ba97383423273b15d3649bddbd5c","width":400,"height":142}},"href":"https://mma.prnewswire.com/media/729436/Orsini_New_logo_color_fa_ID_e6fa151cc036.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"MPS II is a genetic metabolic condition in which the body does not produce enough of the enzymes required to break down sugars into simpler molecules. Over time, sugar molecules called glycosaminoglycans collect in the cells, blood and connective tissues, resulting in progressive cellular damage. This damage affects patients' physical abilities and organ and system functioning, as well as cognitive development. AVLAYAH is a brain-penetrant enzyme replacement therapy designed to assist in breaking down these sugar molecules and prevent further buildup. It is the twentieth enzyme replacement therapy, an...